Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Main|Search|PHGKB
Search PHGKB:

Last Posted: Oct 25, 2022
spot light Highlights

ALS therapy hits molecular mark but misses clinical one
K O'Leary, Nature Medicine, October 3, 2022

At week 24, those receiving tofersen showed a reduction in concentrations of toxic SOD1 protein and markers of neuronal injury. Despite this, there was no significant difference in the primary endpoint — the rate of functional decline (according to the ALS Functional Rating Scale-Revised) – between the tofersen group (-6.98 points) and the placebo group (-8.14 points).

Biomarker data prove critical for ALS drug evaluation at FDA.
Carvalho Thiago et al. Nature medicine 2022 9

All the proposed and approved treatments aim to slow a patient’s rate of functional decline and prolong life, but reversing damage in neurodegenerative conditions is a more elusive goal. A better understanding of ALS should lead to earlier detection and treatment, stopping or slowing the disease before patients develop a severe, progressive loss of motor function.

A machine-learning based objective measure for ALS disease severity
FG Vieira et al, NPJ Digital Medicine, April 8, 2022

We developed a machine learning (ML) based objective measure for ALS disease severity based on voice samples and accelerometer measurements from a four-year longitudinal dataset. 584 people living with ALS consented and carried out prescribed speaking and limb-based tasks. 542 participants contributed 5814 voice recordings, and 350 contributed 13,009 accelerometer samples, while simultaneously measuring ALSFRS-R scores.

Predictive genetic testing for Motor neuron disease: time for a guideline?
A McNeil et al, EJHG, April 5, 2022

Until recently, predictive testing for motor neuron disease (MND, also known as amyotrophic lateral sclerosis (ALS)) was available to only a small proportion of families who had a known disease causing genetic variant in a limited group of causal genes (e.g. SOD1). However, the application of newer genomic technologies has identified many more genes linked to MND (e.g. c9orf72). Even in the absence of a family history of MND, comprehensive genomic approaches (c9orf72 expansion testing, followed by gene panel testing) can identify a causal genetic variant in around 20% of MND probands of Western European ethnicity.


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP